CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

She's going to have good arms!' I was ten years old and standing in my parents' bathroom when I heard my mother say this.

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...